Muscarinic receptors in schizophrenia

Current Molecular Medicine

Volumn 3, Issue 5, 2003, Pages 419-426

  Dean, B ^a,c,d   Bymaster, F P ^b   Scarr, E ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b ELI LILLY AND COMPANY   (United States)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

3H pirenzipine binding receptor knockout antipsychotic drugs cognition; Acetylcholine muscarinic receptors schizophrenia frontal cortex

Indexed keywords

6 (3 PROPYLTHIO 1,2,5 THIADIAZOL 4 YL) 1 AZABICYCLO[3.2.1]OCTANE; ACETYLCHOLINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHYSOSTIGMINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE;

ANIMAL BEHAVIOR; BEHAVIOR DISORDER; BRAIN REGION; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG RESPONSE; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IMAGING SYSTEM; KNOCKOUT MOUSE; NONHUMAN; PHARMACEUTICAL ENGINEERING; PROTEIN FAMILY; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM; HUMANS; MICE; MICE, KNOCKOUT; MULTIGENE FAMILY; RATS; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA;

ANIMALIA;

EID: 0042562047     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566524033479654     Document Type: Review

References (82)

1. Cohen, L.H., Thale, T. and Tissenbaum, M.J. (1944) Arch. Neurol. Psychiatry, 51, 171-175.
2. Tandon, R. (1999) Br. J. Psychiatry Suppl., 37, 7-11.
3. Edelstein, P., Schultz, J.R., Hirschowitz, J., Kanter, D.R. and Garver, D.L. (1981) Am. J. Psychiatry, 138, 1078-1081.
4. Kane, J.M. and McGlashan, T.H. (1995) Lancet, 346, 820-825.
5. Clozapine Study Group (1993) Br. J. Psychiatry, 163, 150-154.
6. Ashby, C.R., Jr. and Wang, R.Y. (1996) Synapse, 24, 349-394.
7. Bymaster, F.P., Felder, C.C., Ahmed, S. and McKenzie, D. (2002) Current Drug Targets - CNS & Neurological Disorders, 1, 147-164.
8. Caulfield, M.P. and Birdsall, N.J. (1998) Pharmacol. Rev., 50, 279-290.
9. Levine, R.R. and Birdsall, N.J. (2003) Trends Pharmacol. Sci., 10 (Suppl. 7), S1-S119.
10. Wei, J., Walton, E.A., Milici, A. and Buccafusco, J.J. (1994) J. Neurochem., 63, 815-821.
11. Ndoye, A., Buchli, R., Greenberg, B., Nguyen, V.T., Zia, S., Rodriguez, J.G., Webber, R.J., Lawry, M.A. and Grando, S.A. (1998) J. Invest Dermatol., 111. 410-416.
12. Buchli, R., Ndoye, A., Rodriguez, J.G., Zia, S., Webber, R.J. and Grando, S.A. (1999) J. Cell Biochem., 74, 264-277.
13. Buchli, R., Ndoye, A., Arredondo, J., Webber, R.J. and Grando, S.A. (2001) Mol. Cell Biochem., 228, 57-72.
14. Flynn, D.D., Ferrari-DiLeo, G., Mash, D.C. and Levey, A.I. (1995) J. Neurochem., 64, 1888-1891.
15. Bennett, J.P. Jr., Enna, S.J., Bylund, D.B., Gillin, J.C., Wyatt, R.J. and Snyder, S.H. (1979) Arch. Gen. Psychiatry, 36, 927-934.
16. Ellis, J., Huyler, J. and Brann, M.R. (1991) Biochem. Pharmacol., 42, 1927-1932.
17. Watanabe, S., Nishikawa, T., Takashima, M. and Toru, M. (1983) Life Sci., 33, 2187-2196.
18. Toru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio, H., Ichikawa, H., Kurumaji, A., Takashima, M., Mataga, N. and Ogawa, A. (1988) Acta Psychiatr. Scand., 78, 121-137.
19. Crook, J.M., Dean, B., Pavey, G. and Copolov, D. (1999) Life Sci., 64, 1761-1771.
20. Levey, A.I., Kitt, C.A., Simonds, W.F., Price, D.L. and Brann, M.R. (1991) J. Neurosci., 11, 3218-3226.
21. Dean, B., Crook, J.M., Opeskin, K., Hill, C., Keks, N. and Copolov, D. L. (1996) Mol. Psychiatry, 1, 54-58.
22. Crook, J.M., Tomaskovic-Crook, E., Copolov, D.L. and Dean, B. (2000) Biol. Psychiatry, 48, 381-388.
23. Crook, J.M., Tomaskovic-Crook, E., Copolov, D.L. and Dean, B. (2001) Am. J. Psychiatry, 158, 918-925.
24. Dean, B., McLeod, M., Keriakous, D., McKenzie, J. and Scarr, E. (2002) Mol. Psychiatry, 7, 1083-1091.
25. See, R.E., Toga, A.W. and Ellison, G. (1990) J. Neural Transm. Gen. Sect., 82, 93-109.
26. Muller, P. and Seeman, P. (1977) Life Sci., 21, 1751-1758.
27. Rupniak, N.M., Briggs, R.S., Petersen, M.M., Mann, S., Reavill, C., Jenner, P. and Marsden, C.D. (1986) Clin. Neuropharmacol., 9, 282-292.
28. Boyson, S.J., McGonigle, P., Luthin, G.R., Wolfe, B.B. and Molinoff, P.B. (1988) J. Pharmacol. Exp. Ther., 244, 987-993.
29. Akiyama, K., Sato, M., Yamada, N. and Otsuki, S. (1987) Jpn. J. Psychiatry Neurol., 41, 311-320.
30. Raedler, T.J., Knable, M.B., Jones, D.W., Urbina, R.A., Gorey, J.G., Lee, K.S., Egan, M.F., Coppola, R. and Weinberger, D.R. (2003) Am. J. Psychiatry, 160, 118-127.
31. Hamilton, S.E. and Nathanson, N.M. (2001) J. Biol. Chem., 276, 15850-15853.
32. Hamilton, S.E., Loose, M.D., Qi, M., Levey, A.I., Hille, B., McKnight, G.S., Idzerda, R.L. and Nathanson, N.M. (1997) Proc. Natl. Acad. Sci. USA, 94, 13311-13316.
33. Hamilton, S.E., Hardouin, S.N., Anagnostaras, S.G., Murphy, G.G., Richmond, K.N., Silva, A.J., Feigl, E.O. and Nathanson, N.M. (2001) Life Sci., 68, 2489-2493.
34. Gillette, M.U., Buchanan, G.F., Artinian, L., Hamilton, S.E., Nathanson, N.M. and Liu, C. (2001) Life Sci., 68, 2467-2472.
35. Gomeza, J., Shannon, H., Kostenis, E., Felder, C., Zhang, L., Brodkin, J., Grinberg, A., Sheng, H. and Wess, J. (1999) Proc. Natl. Acad. Sci. USA, 96, 1692-1697.
36. Hemrick-Luecke, S.K., Bymaster, F.P., Evans, D.C., Wess, J. and Felder, C.C. (2002) J. Pharmacol. Exp. Ther., 303, 99-103.
37. Basile, A.S., Fedorova, I., Zapata, A., Liu, X., Shippenberg, T., Duttaroy, A., Yamada, M. and Wess, J. (2002) Proc. Natl. Acad. Sci. USA, 99, 11452-11457.
38. Duke, P.J., Pantelis, C., McPhillips, M.A. and Barnes, T.R. (2001) Br. J. Psychiatry, 179, 509-513.
39. Porter, A.C., Bymaster, F.P., DeLapp, N.W., Yamada, M., Wess, J., Hamilton, S.E., Nathanson, N.M. and Felder, C.C. (2002) Brain Res., 944, 82-89.
40. Shapiro, M.S., Loose, M.D., Hamilton, S.E., Nathanson, N.M., Gomeza, J., Wess, J. and Hille, B. (1999) Proc. Natl. Acad. Sci. USA, 96, 10899-10904.
41. Gomeza, J., Zhang, L., Kostenis, E., Felder, C.C., Bymaster, F.P., Brodkin, J., Shannon, H., Xia, B., Duttaroy, A., Deng, C.X. and Wess, J. (2001) Life Sci., 68, 2457-2466.
42. Zhang, W., Yamada, M., Gomeza, J., Basile, A.S. and Wess, J. (2002) J. Neurosci., 22, 6347-6352.
43. Meltzer, H.Y. and Stahl, S.M. (1976) Schizophr.Bull., 2, 19-76.
44. Chan, A.S., Kwok, I.C., Chiu, H., Lam, L., Pang, A. and Chow, L.Y. (2000) Schizophr. Res., 41, 431-445.
45. Rao, M.L., Gross, G., Strebel, B., Halaris, A., Huber, G., Braunig, P. and Marler, M. (1994) Biol. Psychiatry, 35, 151-163.
46. Mills, J.N., Morgan, R., Minors, D.S. and Waterhouse, J.M. (1977) Chronobiologia, 4, 353-360.
47. Morgan, R. and Cheadle, A.J. (1976) Br. J. Psychiatry, 129, 350-354.
48. Shiloh, R., Portuguese, S., Bodinger, L., Katz, N., Sigler, M., Hermesh, H., Munitz, H. and Weizman, A. (2003) Eur. Neuropsychopharmacol., 13, 49-52.
49. Klett, C.J. and Caffey, E. Jr. (1972) Arch. Gen. Psychiatry, 26, 374-379.
50. Bolden, C., Cusack, B. and Richelson, E. (1992) J. Pharmacol. Exp. Ther., 260, 576-580.
51. Zorn, S.H., Jones, S.B., Ward, K.M. and Liston, D.R. (1994) Eur. J. Pharmacol., 269, R1-R2.
52. Bodick, N.C., Offen, W.W., Levey, A.I., Cutler, N.R., Gauthier, S.G., Satlin, A., Shannon, H.E., Tollefson, G.D., Rasmussen, K., Bymaster, F.P., Hurley, D.J., Potter, W.Z. and Paul, S.M. (1997) Arch.Neurol. 54, 465-473.
53. Pantelis, C., Barnes, T.R., Nelson, H.E., Tanner, S., Weatherley, L., Owen, A.M. and Robbins, T.W. (1997) Brain, 120, 1823-1843.
54. Bymaster, F.P., Shannon, H.E., Rasmussen, K., DeLapp, N.W., Mitch, C.H., Ward, J.S., Calligaro, D.O., Ludvigsen, T.S., Sheardown, M.J., Olesen, P.H., Swedberg, M.D., Sauerberg, P. and Fink-Jensen, A. (1998) Eur. J. Pharmacol., 356, 109-119.
55. Shannon, H.E., Rasmussen, K., Bymaster, F.P., Hart, J.C., Peters, S.C., Swedberg, M.D., Jeppesen, L., Sheardown, M.J., Sauerberg, P. and Fink-Jensen, A. (2000) Schizophr. Res., 42, 249-259.
56. Parada, M.A., Hernandez, L., Puig, d.P., Rada, P. and Murzi, E. (1997) J. Pharmacol. Exp. Ther., 281, 582-588.
57. Ichikawa, J., Dai, J., O'Laughlin, I.A., Fowler, W.L. and Meltzer, H.Y. (2002) Neuropsychopharmacology, 26, 325-339.
58. Shirazi-Southall, S., Rodriguez, D.E. and Nomikos, G.G. (2002) Neuropsychopharmacology, 26, 583-594.
59. Bymaster, F.P. and Falcone, J.F. (2000) Eur. J. Pharmacol., 390, 245-248.
60. Kennedy, J.S., Bymaster, F.P., Schuh, L., Calligaro, D.O., Nomikos, G., Felder, C.C., Bernauer, M., Kinon, B.J., Baker, R.W., Hay, D., Roth, H.J., Dossenbach, M., Kaiser, C., Beasley, C.M., Holcombe, J.H., Effron, M.B. and Breier, A. (2001) Int. J. Geriatr. Psychiatry, 16 (Suppl. 1), S33-S61.
61. Baghdoyan, H.A., Lydic, R. and Fleegal, M.A. (1998) J. Pharmacol. Exp. Ther., 286, 1446-1452.
62. Billard, W., Binch, H. III, Crosby, G. and McQuade, R.D. (1995) J. Pharmacol. Exp. Ther., 273, 273-279.
63. Iannazzo, L. and Majewski, H. (2000) Neurosci. Lett., 287, 129-132.
64. Douglas, C.L., Baghdoyan, H.A. and Lydic, R. (2001) J. Pharmacol. Exp. Ther., 299, 960-966.
65. Laruelle, M., Abi-Dargham, A., van Dyck, C.H., Gil, R., D'Souza, C.D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S.S., Baldwin, R.M., Seibyl, J.P., Krystal, J.H., Charney, D.S. and Innis, R.B. (1996) Proc. Natl. Acad. Sci. USA, 93, 9235-9240.
66. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., Marsh, R.D., Moore, N.A., Tye, N.C., Seeman, P. and Wong, D.T. (1996) Neuropsychopharmacology, 14, 87-96.
67. Schotte, A., Bonaventure, P., Janssen, P.F. and Leysen, J.E. (1995) Jpn. J. Pharmacol., 69, 399-412.
68. Hirano, H., Day, J. and Fibiger, H.C. (1995) J. Neurochem., 65, 1139-1145.
69. Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T. and Altar, C.A. (2002) Eur. J. Pharmacol., 441, 137-140.
70. Ichikawa, J., Dai, J., O'Laughlin, I.A., Fowler, W.L. and Meltzer, H.Y. (2002) Neuropsychopharmacology, 26, 325-339.
71. Ichikawa, J., Dai, J. and Meltzer, H.Y. (2002) Brain Res., 939, 34-42.
72. Perry, E., Walker, M., Grace, J. and Perry, R. (1999) Trends Neurosci., 22, 273-280.
73. Piggott, M., Owens, J., O'Brien, J., Paling, S., Wyper, D., Fenwick, J., Johnson, M., Perry, R. and Perry, E. (2002) J. Chem. Neuroanat., 24, 211-223.
74. Rodriguez-Puertas, R., Pascual, J., Vilaro, T. and Pazos, A. (1997) Synapse, 26, 341-350.
75. Schwarz, R.D., Callahan, M.J., Coughenour, L.L., Dickerson, M.R., Kinsora, J.J., Lipinski, W.J., Raby, C.A., Spencer, C.J. and Tecle, H. (1999) J. Pharmacol. Exp. Ther., 291, 812-822.
76. Eglen, R.M., Choppin, A. and Watson, N. (2001) Trends Pharmacol. Sci., 22, 409-414.
77. Bymaster, F.P., Shannon, H.E., Rasmussen, K., DeLapp, N.W., Ward, J.S., Calligaro, D.O., Mitch, C.H., Whitesitt, C., Ludvigsen, T.S., Sheardown, M., Swedberg, M., Rasmussen, T., Olesen, P.H., Jeppesen, L., Sauerberg, P. and Fink-Jensen, A. (1999) Life Sci., 64, 527-534.
78. Olianas, M.C. and Onali, P. (1999) Life Sci., 65, 2233-2240.
79. Tandon, R. (2002) Psychiatr.Q., 73, 297-311.
80. Kirrane, R.M., Mitropoulou, V., Nunn, M., Silverman, J. and Siever, L.J. (2001) Schizophr. Res., 48, 1-5.
81. Buchanan, R.W., Summerfelt, A., Tek, C. and Gold, J. (2003) Schizophr. Res., 59, 29-33.
82. Leonard, S., Adams, C., Breese, C.R., Adler, L.E., Bickford, P., Byerley, W., Coon, H., Griffith, J.M., Miller, C., Myles-Worsley, M., Nagamoto, H.T., Rollins, Y., Stevens, K.E., Waldo, M. and Freedman, R. (1996) Schizophr. Bull., 22, 431-445.